RNXT · RenovoRx, Inc.
$1.20
-0.20 (-14.29%)
At close · Aug 17
Market Cap
$63.18M
Shares
45.13M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$1.12M
+2511.6%
FY2025
Net Income
-$11.17M
-26.7%
FY2025
Gross Margin
70.88%
-29.1pp
FY2025
Operating Margin
-1113.98%
+24397.6pp
FY2025
Diluted EPS
-$0.32
+20%
FY2025
Operating Cash Flow
-$10.97M
-20.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|---|
| $3.75M – $4.25M | $1.98M | $1.12M | $43K | — | — | — | — | |
| — | — | — | — | — | — | -$834K | -$587K | |
| — | $308K | $327K | $0 | — | — | — | — | |
| — | $1.67M | $796K | $43K | — | — | — | — | |
| — | — | 70.88% | 100% | — | — | — | — | |
| — | $5.63M | $6.27M | $6.03M | $5.67M | $4.3M | $3.04M | $2.39M | |
| — | $4.89M | — | — | $5.73M | $5.65M | $2.63M | $818K | |
| — | $9.58M | $7.04M | $4.99M | $5.73M | — | — | — | |
| — | — | $2M | $0 | — | — | — | — | |
| — | $15.21M | $13.31M | $11.01M | $11.4M | $9.95M | $5.67M | $3.2M | |
| — | -$13.54M | -$12.51M | -$10.97M | -$11.4M | -$9.95M | -$5.67M | -$3.2M | |
| — | — | -1113.98% | -25511.63% | — | — | — | — | |
| — | — | -$10.51M | -$10.97M | — | — | — | — | |
| — | $1.26M | $1.34M | $2.16M | $1.16M | $61K | -$653K | -$594K | |
| — | — | -$11.17M | -$8.75M | — | — | — | — | |
| — | — | $2000 | — | — | — | — | — | |
| — | -$12.29M | -$11.17M | -$8.81M | -$10.23M | -$9.89M | -$6.32M | -$3.8M | |
| — | — | -994.48% | -20497.67% | — | — | — | — | |
| — | — | -$11.17M | -$8.81M | -$10.23M | -$9.87M | -$6.32M | — | |
| USD/shares | — | — | -$0.32 | -$0.40 | -$0.99 | -$1.09 | -$1.21 | — |
| USD/shares | — | — | -$0.32 | -$0.40 | -$0.99 | -$1.09 | — | — |
| shares | — | — | 35.33M | 22.27M | 10.29M | 9.05M | 5.22M | 2.21M |
| shares | — | — | 35.33M | 22.27M | 10.29M | 9.05M | 5.22M | 2.21M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.02×
EV/EBIT
—
Peer median 17.68×
P/E (TTM)
—
Peer median 9.02×
Peer medians compare against the 302 similar-size Biotechnology companies (of 545 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| All Other Segments | $1,123,000 | $43,000 |
Key facts
CIK
1574094
CUSIP
75989R107
13F (30d)
27 filings
27 filers
Visit website
Investor relations